Drugs / KM257
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05320874 | Apr 2022 → Jun 2024 overdue | — | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05320874 ↗ |
| Route | Intravenous | “intravenously administrated” NCT05320874 ↗ |